| You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here. Prefer to view this content on our website? Click here.
Dear Fellow Investor,
Company: Hims & Hers Health (SYM: HIMS) Shares of Hims & Hers Health (SYM: HIMS) just dropped about 20%. All on news the Ozempic shortage is over. Just last week, the US FDA said Novo Nordisk’s diabetes and weight loss drugs Ozempic and Wegovy are no longer in shortage. That means Hims & Hers Health, which markets compounded versions of the two treatments, can no longer manufacture exact copies of the drugs as they did during the shortage. It also means the gravy train is over for HIMS, at least for now. During the shortage, “patients flocked to compounders, which were allowed to make copies of semaglutide since it was on the shortage list. Patients were also drawn to compounded semaglutide since it was cheaper than the brand-name version, which carries a list price of about $1,000 a month,” as noted by StatNews.com. The Financial Newsletter Team FREE Report: Top 4 Gold Stocks Ready to Surge in 2025
Gold prices have climbed steadily for the past two years – soaring to a record-high of $2,700 at the end of 2024 – with no sign of slowing down. In fact, Goldman Sachs has predicted gold will reach $2,900/oz. here in early 2025 and both Citibank and Bank of America calling for $3,000 gold here in 2025. And CNBC has stated: Gold prices hit an all-time high on Monday, bolstered by safe-haven inflows after U.S. President Donald Trump’s tariffs on Canada, China and Mexico added to concerns of inflation that would dent economic growth. So how should you invest for maximum potential upside during these precarious times? I’ve prepared a Free Report that reveals the 4 top gold stocks poised to soar as gold prices continue to climb amid financial uncertainty.
(By clicking the links above, you agree to receive future emails from us and our partners. You can opt out at any time.) Demand is Still Sky-High for Obesity Drugs With demand not showing any signs of cooling, companies could see supply issues again down the road, which could be good news for companies like HIMS. For one, we have to consider the obesity market opportunity is substantial. As noted by Goldman Sachs, the global obesity treatment market could grow to $130 billion by 2030. Even Morgan Stanley expects the global obesity drug treatment market to reach $105 billion by 2030 from $77 billion. At the high end, $144 billion. (More info below ad) Investors Alley What Elon Musk doesn’t want investors to know
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works? Click here to uncover Tesla's hidden income secret. Two, companies like Novo Nordisk are seeing record sales for Wegovy and Ozempic, leaving the company struggling to keep up with demand. “Obesity drug sales jumped by 154% at constant exchange rates to 41.6bn Danish kroner (£4.8bn) last year, fueled by demand for Wegovy, which brought in £3.6bn. Sales of diabetes drugs such as Ozempic grew by 52%, and obesity and diabetes drug sales totalled nearly £25bn,” according to The Guardian. Again, while it may be a good idea to avoid the HIMS stock for now, keep an eye on it. Mode Mobile Today’s Fastest Growing Company Might Surprise You
🚨 No, it's not the publicly traded tech giant you might expect… Meet $MODE, the disruptor turning phones into potential income generators. Investors are buzzing about the company's pre-IPO offering. 📲 Mode saw 32,481% revenue growth from 2019 to 2022, ranking them the #1 overall software company on Deloitte’s most recent fastest-growing companies list by aiming to pioneer "Privatized Universal Basic Income" powered by technology — not government. Their flagship product, EarnPhone, has already helped consumers earn & save $325M+. 🚀 Space is limited and Mode is 95% towards their $20M milestone! Now is the time to secure your spot at $0.26/share. Weight-loss biotechs have seen big gains in past years. Are there any other health-related stocks you think are hot right now? Hit "reply" to this email and let us know! | 